Compare Gilead Sciences, Inc. (GILD) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs J M Smucker Co — how do they compare? Gilead Sciences, Inc. trades at $149.66 (market cap $182.40B), while J M Smucker Co trades at $118.42 (market cap $12.76B). The key difference: Gilead Sciences, Inc. is far larger — about 14.3× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (3.75%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and J M Smucker Co for 74 Days on average.
| GILD | SJM | |
|---|---|---|
Market Cap | $182.40B | $12.76B |
Volume | 4,469,821 | 1,300,545 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $132.34 |
52-Week Low | $116.74 | $89.53 |
Typical Hold Time | 111 Days | 74 Days |
Enterprise Value | $205.46B | $19.61B |
Dividend Yield | 2.23% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
SJM trades at $115.93, down 0.74% on the day, with a bearish technical signal and recent earnings beats. The company reported a net loss of $1.23 billion in 2025 despite revenue growth to $8.73 billion, though 2026 forecasts show a return to profitability. Analyst consensus is bullish with a $138.23 price target, and a $1.12 dividend is scheduled for September 2026.
The stock presents a mixed outlook: strong analyst support and dividend yield offer upside, but high P/E of 55.8 and recent net losses pose valuation and execution risks. Key catalysts include sustained earnings growth and margin improvement, while competitive pressures and debt levels remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
